iCAT for Recurrent/Refractory/HR Solid Tumors



Status:Recruiting
Conditions:Cancer, Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 30
Updated:1/1/2014
Start Date:August 2012
Contact:Katherine Janeway, MD
Email:kjaneway@partners.org
Phone:617-632-4994

Use our guide to learn which trials are right for you!

Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors

In this study tumor will be tested for cancer causing gene alterations such as mutations or
copy number alterations. This is called tumor profiling. A panel of experts will review the
tumor profiling results and determine whether there is a cancer-causing alteration present
in the tumor. If there is, the experts will determine if there is a targeted drug available
that could counteract this alteration. If there is an alteration identified and a targeted
drug available the panel of experts will make an individualized treatment recommendation.
The results of the tumor profiling and the individualized treatment recommendation can be
shared with the primary oncologist.

Some cancer-causing gene alterations (such as mutations or copy number alterations) are
common or occur repeatedly in different types of cancers. For some of these alterations
there are drugs, called targeted drugs that specifically counteract the alteration. In
certain cancer types, these targeted drugs are very effective at fighting the cancer.

A tumor specimen that has been obtained previously or is planned to be obtained as part of
clinical care will be used to perform tumor profiling. Additional procedures to obtain tumor
will not be performed. An expert panel will review the results of the tumor profiling tests
and determine whether a cancer-causing alteration is present and whether an individualized
treatment recommendation can be made. If consent to sharing of the tumor profiling results
and individualized treatment recommendation is provided then a study physician will discuss
the profiling results and the individualized treatment recommendation with the primary
oncologist. In addition, the primary oncologist will receive a letter detailing the tumor
profiling results and the individualized treatment recommendation.

Inclusion Criteria:

- Diagnosis of recurrent, refractory of high risk pediatric solid tumor (excluding
brain tumor)

- Histologic proof of malignancy at the time of diagnosis or recurrence

- Sufficient tumor specimen available for profiling from diagnosis or recurrence, or
surgery/biopsy planned for clinical care

Exclusion Criteria:

- Brain tumors
We found this trial at
5
sites
533 Parnassus Ave
San Francisco, California 94122
(415) 476-9000
University of California - San Francisco The leading university exclusively focused on health, UC San...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials